Given that MEK is a major downstream mediator of oncogenic BRAF in the MAPK signaling pathway, we cannot exclude the possibility that the same mechanism is involved in the development of resistance to BRAF inhibitor vemurafenib in RKO colon cancer cells harboring BRAFV600E mutation. This evidence concerns the gene BRAF and malignant colon neoplasm.